XML 77 R62.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Collaboration and Licensing Arrangements - Additional Information (Detail) |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | ---
Dec. 30, 2016 USD ($) | May 31, 2018 | Dec. 31, 2018 USD ($) | Sep. 30, 2018 USD ($) | Jun. 30, 2018 USD ($) | Mar. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Sep. 30, 2017 USD ($) | Jun. 30, 2017 USD ($) | Mar. 31, 2017 USD ($) | Dec. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Dec. 31, 2016 USD ($) Milestone | Oct. 16, 2018 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net revenue - commercial product sales |  |  | $ 16,031,000 | $ 4,469,000 | $ 3,893,000 | $ 3,465,000 | $ 4,530,000 | $ 2,043,000 | $ 2,163,000 | $ 3,009,000 | $ 27,859,000 | $ 11,745,000 | $ 174,758,000 |
Deferred payments from collaborations - current |  |  | 36,885,000 |  |  |  | 250,000 |  |  |  | 36,885,000 | 250,000 |  |
Deferred payments from collaborations - long term |  |  | 10,680,000 |  |  |  | $ 500,000 |  |  |  | 10,680,000 | 500,000 |  |
Income Taxes Paid |  |  |  |  |  |  |  |  |  |  | 240,000 | 51,000 |  |
Sanofi-Aventis Deutschland GmbH | Put Option |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment for insulin put option |  |  |  |  |  |  |  |  |  | $ 30,600,000 |  |  |  |
AFREZZA product sales |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net revenue - commercial product sales |  |  |  |  |  |  |  |  |  |  | 17,276,000 | $ 9,192,000 | 1,895,000 |
Collaboration and License Agreement | Sanofi-Aventis Deutschland GmbH |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition upfront payment |  |  |  |  |  |  |  |  |  |  |  |  | $ 150,000,000 |
Number of milestone | Milestone |  |  |  |  |  |  |  |  |  |  |  |  | 2 |
Collaboration and License Agreement | Sanofi-Aventis Deutschland GmbH | Operating loss Sharing |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue offset in collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  | $ 64,900,000 |
Collaboration and License Agreement | Receptor |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred payments from collaboration |  |  | 500,000 |  |  |  |  |  |  |  | 500,000 |  |  |
Deferred payments from collaborations - current |  |  | 300,000 |  |  |  |  |  |  |  | 300,000 |  |  |
Nonrefundable option exercise and license fee | $ 1,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and License Agreement | Milestone Payment One | Sanofi-Aventis Deutschland GmbH |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition milestone payment |  |  |  |  |  |  |  |  |  |  |  |  | 25,000,000 |
Collaboration and License Agreement | Milestone Payment Two | Sanofi-Aventis Deutschland GmbH |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognition milestone payment |  |  |  |  |  |  |  |  |  |  |  |  | 25,000,000 |
Collaboration and License Agreement | AFREZZA product sales | Sanofi-Aventis Deutschland GmbH |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue offset in collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  | 17,500,000 |
Collaboration and License Agreement | Insulin Put | Sanofi-Aventis Deutschland GmbH |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue offset in collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  | $ 19,400,000 |
Collaboration and License Agreement | United Therapeutics Corporation |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 45,000,000
Net revenue - commercial product sales |  |  |  |  |  |  |  |  |  |  | 6,400,000 |  |  |
Deferred payments from collaboration |  |  | 38,600,000 |  |  |  |  |  |  |  | 38,600,000 |  |  |
Deferred payments from collaborations - current |  |  | 30,500,000 |  |  |  |  |  |  |  | 30,500,000 |  |  |
Deferred payments from collaborations - long term |  |  | 8,100,000 |  |  |  |  |  |  |  | 8,100,000 |  |  |
Total transaction price |  |  | 97,500,000 |  |  |  |  |  |  |  | 97,500,000 |  |  |
Collaboration and License Agreement | United Therapeutics Corporation | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payments to be receive |  |  | 50,000,000 |  |  |  |  |  |  |  | 50,000,000 |  |  |
Additional option exercise and development milestone payments to be receive |  |  | 40,000,000 |  |  |  |  |  |  |  | 40,000,000 |  |  |
Research Agreement | United Therapeutics Corporation |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  | 10,000,000 |  |  |  |  |  |  |  |  |  |
Net revenue - commercial product sales |  |  |  |  |  |  |  |  |  |  | 3,800,000 |  |  |
Deferred payments from collaboration |  |  | 10,000,000 |  |  |  |  |  |  |  | 10,000,000 |  |  |
Deferred payments from collaborations - current |  |  | 6,000,000 |  |  |  |  |  |  |  | 6,000,000 |  |  |
Deferred payments from collaborations - long term |  |  | 200,000 |  |  |  |  |  |  |  | 200,000 |  |  |
Total transaction price |  |  | 10,000,000 |  |  |  |  |  |  |  | 10,000,000 |  |  |
Research Agreement | United Therapeutics Corporation | Product Prototype |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total transaction price |  |  | 9,000,000 |  |  |  |  |  |  |  | $ 9,000,000 |  |  |
Revenue performance obligation, method used |  |  |  |  |  |  |  |  |  |  | The revenue for the product prototype is recognized using a proportional performance method (based on an estimated percentage of the Company’s efforts required in relation toward overall satisfaction of the obligation). The Company believes that this method best reflects the measure of progress toward complete satisfaction of the performance obligation. |  |  |
Research Agreement | United Therapeutics Corporation | Engineering Consulting Services |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total transaction price |  |  | 1,000,000 |  |  |  |  |  |  |  | $ 1,000,000 |  |  |
Revenue performance obligation, method used |  |  |  |  |  |  |  |  |  |  | The revenue for the engineering consulting services is recognized using a ratable method until the obligation is satisfied and the Company believes that this method best reflects the measure of progress toward complete satisfaction of the performance obligation. |  |  |
Research Agreement | United Therapeutics Corporation | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional milestone payments to be received |  |  |  | $ 30,000,000 |  |  |  |  |  |  |  |  |  |
Distribution Agreement | Foreign Country | India Tax Authority |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Income Taxes Paid |  |  |  |  |  |  |  |  |  |  | $ 200,000 |  |  |
Distribution Agreement | Cipla Ltd |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred payments from collaboration |  |  | 2,100,000 |  |  |  |  |  |  |  | 2,100,000 |  |  |
Deferred payments from collaborations - current |  |  | $ 100,000 |  |  |  |  |  |  |  | $ 100,000 |  |  |
Marketing and distribution agreement date |  | 2018-05 |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Additional milestone payments to be received. + References No definition available. + Details
Name: | mnkd_AdditionalMilestonePaymentsToBeReceived
Namespace Prefix: | mnkd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Additional option exercise and development milestone payments to be received. + References No definition available. + Details
Name: | mnkd_AdditionalOptionExerciseAndDevelopmentMilestonePaymentsToBeReceived
Namespace Prefix: | mnkd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Date of agreement initiation for marketing and distribution. + References No definition available. + Details
Name: | mnkd_DateOfAgreementInitiationForMarketingAndDistribution
Namespace Prefix: | mnkd_
Data Type: | xbrli:gYearMonthItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of milestone. + References No definition available. + Details
Name: | mnkd_NumberOfMilestone
Namespace Prefix: | mnkd_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential milestone payments to be received. + References No definition available. + Details
Name: | mnkd_PotentialMilestonePaymentsToBeReceived
Namespace Prefix: | mnkd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Proceeds from option exercise and license fees received. + References No definition available. + Details
Name: | mnkd_ProceedsFromOptionExerciseAndLicenseFeesReceived
Namespace Prefix: | mnkd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Revenue offset in collaboration agreement. + References No definition available. + Details
Name: | mnkd_RevenueOffsetInCollaborationAgreement
Namespace Prefix: | mnkd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Revenue recognition milestone payment. + References No definition available. + Details
Name: | mnkd_RevenueRecognitionMilestonePayment
Namespace Prefix: | mnkd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue recognition upfront payment. + References No definition available. + Details
Name: | mnkd_RevenueRecognitionUpfrontPayment
Namespace Prefix: | mnkd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront payment received. + References No definition available. + Details
Name: | mnkd_UpfrontPaymentReceived
Namespace Prefix: | mnkd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044 + Details
Name: | us-gaap_ContractWithCustomerLiabilityNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585 + Details
Name: | us-gaap_IncomeTaxesPaid
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow for derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 23 -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3505-108585 + Details
Name: | us-gaap_PaymentsForDerivativeInstrumentFinancingActivities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Description of method used to recognize revenue for performance obligation that is satisfied over time. Includes, but not is limited to, output or input method. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130563-203045 + Details
Name: | us-gaap_RevenuePerformanceObligationSatisfiedOverTimeMethodUsedDescription
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | dei_LegalEntityAxis=mnkd_SanofiAventisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_OpenOptionContractsWrittenTypeAxis=us-gaap_PutOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mnkd_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetsSoldUnderAgreementsToRepurchaseAxis=mnkd_OperatingLossSharingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mnkd_ReceptorLifeScienceIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mnkd_MilestonePaymentOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mnkd_MilestonePaymentTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mnkd_InsulinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mnkd_UnitedTherapeuticsCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mnkd_ResearchAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mnkd_ProductPrototypeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mnkd_EngineeringConsultingServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mnkd_DistributionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_MinistryOfFinanceIndiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mnkd_CiplaLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |